ASCO To Take A Closer Look At Patient-Reported Outcomes In Clinical Trials And Cancer Care
By Joe O’Connell, MD, Vice President and Global Therapeutic Head for Hematology/ Oncology, INC Research/inVentiv Health Clinical Division
While the annual meetings of the American Society of Clinical Oncology (ASCO) can almost always be counted on to generate news about scientific breakthroughs in understanding and treating cancer, the theme for this year’s conference goes beyond that conventional approach. ASCO 2016 Annual Meeting will prominently feature discussions about how clinicians can best integrate recent advances, and particularly how to best assess the impact on real-world patients. This marks a pivotal time during which the cancer community is being challenged to think about drug benefit and risk – and of course, value – in some fundamentally different ways.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.